Get access to our best features
Get access to our best features
Published 9 days ago

Sanders launches investigation into ‘unacceptable’ diabetes, weight loss drug prices

  • The U.S. Senate is investigating Novo Nordisk's high prices for weight loss and diabetes drugs Ozempic and Wegovy.
  • Novo Nordisk charges significantly less for the drugs in other countries than in the U.S., according to Sanders.
  • Senator Sanders called for a reduction in the list and net prices of both Ozempic and Wegovy, questioning the pharmaceutical company's pricing strategies.
Insights by Ground AI
Does this summary seem wrong?

0 Articles

All
Left
Center
Right
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 60% of the sources are Center
60% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)